Rodriguez, Dexter B.
HRN: 14-40-62 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/28/2024
CO-AMOXICLAV 625MG (TAB)
03/28/2024
04/04/2024
PO
625mg
Q8hrs
Multiple Lacerated Wound
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes